Route of administration other than oral for concomitant me­di­cation [Bioanalytics]

posted by Ohlbe – France, 2020-02-05 10:13 (438 d 01:31 ago) – Posting: # 21147
Views: 1,410

Dear Qualityassurance,

» Can anyone suggest me :confused::confused: if it is required to include these medications in concomitant medication experiment if the route of administration is other than oral (e.g. IV, topical, eye drops) during clinical phase?

I would say it depends on the bioavailability of these products when administered by these routes. For IV, no discussion (at least, if there is an active substance - don't bother about saline or glucose). But for a topical administration the answer is likely that there is no point.

Regards
Ohlbe

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,509 registered users;
online 18 (0 registered, 18 guests [including 3 identified bots]).
Forum time: Sunday 12:45 CEST (Europe/Vienna)

Nothing fails like success because you do not learn anything from it.
The only thing we ever learn from is failure.
Success only confirms our superstitions.    Kenneth E. Boulding

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5